VOGENX INC
VOGXNASDAQ🏆 #3411 by market capUS Equity
$19.90▲ $0.59 (+3.06%)
Market closed · at closeTrack VOGX
Get earnings, price moves & breaking news on Telegram
24h▲ 3.1%
7d▲ 12.4%
14d▲ 35.4%
30d▼ 12.7%
ytd—
1y—
🏦Market Cap
$296M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $19.90 – $21.25
- 52-Week Range
- $12.95 – $38.41
- Volume (shares)
- 3,207
- Avg Volume (shares)
- —
- Shares Outstanding
- 14.9M
- Next Earnings
- —
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
VOGENX INC
VOGXFinancial Trends
Financial history unavailable.
StockOtter · stockotter.spaceAbout VOGENX INC
Vogenx is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia (PBH) and gastroparesis. The company's lead product candidate is mizagliflozin, an orally administered, small molecule drug candidate being developed for the treatment of PBH, gastroparesis, and GIP-dependent Cushing's Syndrome.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
8 analysts
Strong Buy2
Buy5
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.